Please login to the form below

Not currently logged in
Email:
Password:

Eisai subsidiary in tie up for prostate cancer antibodies

Eisai subsidiary Morphotek signs a R&D agreement with the National Cancer Institute for the development of therapeutic antibodies to a cancer-associated protein

Morphotek, a subsidiary of Eisai, has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.

Morphotek will apply its proprietary Morphodoma antibody technology to the development of novel therapeutic antibodies for use in the treatment of prostate cancer.

During a long-term research programme into tumour cell biology, NCI researchers discovered several proteins whose expression is prostate-specific. One of these proteins, referred to as ProCa-1, is a gene product that is expressed on the cell surface in normal prostate and prostate cancer cells, but not in other tissues tested.

The gene is expressed in a majority of prostate tumours tested. As part of this CRADA, Morphotek will apply its antibody discovery technology to the development of monoclonal antibodies (mABs) that can bind the ProCa-1 protein and test lead mABs for anti-cancer properties in collaboration with NCI researchers.

Therapeutic leads that show good target binding and tumour specificity will be candidates for possible advancement to preclinical and clinical evaluation.

The NCI will provide its expertise in evaluating the lead antibodies for therapeutic efficacy.

The agreement between NCI and Morphotek is part of an existing collaborative relationship with NCI to develop novel therapies for the treatment of various cancer types.

9th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics